MANAGEMENT OF ENDOCRINE DISEASE: Reversible hypogonadotropic hypogonadism
- PMID: 26792935
- DOI: 10.1530/EJE-15-1033
MANAGEMENT OF ENDOCRINE DISEASE: Reversible hypogonadotropic hypogonadism
Abstract
Congenital hypogonadotropic hypogonadism (CHH) is characterized by lack of puberty and infertility. Traditionally, it has been considered a life-long condition yet cases of reversibility have been described wherein patients spontaneously recover function of the reproductive axis following treatment. Reversibility occurs in both male and female CHH cases and appears to be more common (~10-15%) than previously thought. These reversal patients span a range of GnRH deficiency from mild to severe and many reversal patients harbor mutations in genes underlying CHH. However, to date there are no clear factors for predicting reversible CHH. Importantly, recovery of reproductive axis function may not be permanent. Thus, CHH is not always life-long and the incidence of reversal warrants periodic treatment withdrawal with close monitoring and follow-up. Reversible CHH highlights the importance of environmental (epigenetic) factors such as sex steroid treatment on the reproductive axis in modifying the phenotype. This review provides an overview and an update on what is known about this phenomenon.
© 2016 European Society of Endocrinology.
Similar articles
-
Non-syndromic congenital hypogonadotropic hypogonadism: clinical presentation and genotype-phenotype relationships.Eur J Endocrinol. 2010 May;162(5):835-51. doi: 10.1530/EJE-10-0083. Epub 2010 Mar 5. Eur J Endocrinol. 2010. PMID: 20207726 Review.
-
[Congenital hypogonadotropic hypogonadism and Kallmann syndrome in males].Presse Med. 2014 Feb;43(2):152-61. doi: 10.1016/j.lpm.2013.12.008. Epub 2014 Jan 20. Presse Med. 2014. PMID: 24456696 Review. French.
-
Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment.Nat Rev Endocrinol. 2015 Sep;11(9):547-64. doi: 10.1038/nrendo.2015.112. Epub 2015 Jul 21. Nat Rev Endocrinol. 2015. PMID: 26194704 Review.
-
Recovery of hypothalamic-pituitary-gonadal function with low dose testosterone treatment in a male with congenital hypogonadotropic hypogonadism.Andrologia. 2022 Dec;54(11):e14628. doi: 10.1111/and.14628. Epub 2022 Nov 8. Andrologia. 2022. PMID: 36346040
-
Classes and predictors of reversal in male patients with congenital hypogonadotropic hypogonadism: a cross-sectional study of six international referral centres.Lancet Diabetes Endocrinol. 2024 Apr;12(4):257-266. doi: 10.1016/S2213-8587(24)00028-7. Epub 2024 Mar 1. Lancet Diabetes Endocrinol. 2024. PMID: 38437850
Cited by
-
Psychological Aspects of Congenital Hypogonadotropic Hypogonadism.Front Endocrinol (Lausanne). 2019 Jul 5;10:353. doi: 10.3389/fendo.2019.00353. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31333578 Free PMC article. Review.
-
Approach to the Patient: Management of Pituitary Hormone Replacement Through Transition.J Clin Endocrinol Metab. 2022 Jun 16;107(7):2077-2091. doi: 10.1210/clinem/dgac129. J Clin Endocrinol Metab. 2022. PMID: 35262704 Free PMC article.
-
GnRH receptor gene mutations in adolescents and young adults presenting with signs of partial gonadotropin deficiency.PLoS One. 2017 Nov 28;12(11):e0188750. doi: 10.1371/journal.pone.0188750. eCollection 2017. PLoS One. 2017. PMID: 29182666 Free PMC article.
-
Reproductive Phenotypes and Genotypes in Men With IHH.J Clin Endocrinol Metab. 2023 Mar 10;108(4):897-908. doi: 10.1210/clinem/dgac615. J Clin Endocrinol Metab. 2023. PMID: 36268624 Free PMC article.
-
Review of human genetic and clinical studies directly relevant to GnRH signalling.J Neuroendocrinol. 2022 May;34(5):e13080. doi: 10.1111/jne.13080. Epub 2021 Dec 31. J Neuroendocrinol. 2022. PMID: 34970798 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
